Consistent with classic AD pathologies, it has been suggested that the genetic risk of LOAD, such as APOE and TREM2 status, is functionally associated with the microglial response to amyloid-β pathology (i.e., amyloid-responsive microglia) [12–14]. This evidence concerns the gene APOE and Alzheimer disease.